Page last updated: 2024-12-08

2-(1-octynyl)adenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(1-octynyl)adenosine, also known as **octyl adenosine**, is a synthetic nucleoside analog. It's a modified version of adenosine, a fundamental building block of RNA and DNA, with a long, hydrophobic octynyl chain attached to the adenine base.

**Importance in Research:**

**1. Adenosine Receptor Modulator:** Octyl adenosine acts as a potent and selective antagonist of the A₁ adenosine receptor. This means it blocks the binding of adenosine to the receptor, preventing its activation.

* **Studying Adenosine Receptor Function:** Octyl adenosine is a valuable tool for studying the role of A₁ receptors in various physiological processes. This includes:
* **Neuroprotection:** A₁ receptors are involved in neuroprotection against excitotoxicity and ischemia. Octyl adenosine helps understand these mechanisms.
* **Cardiovascular Function:** A₁ receptors play a role in regulating heart rate, blood pressure, and blood flow. Octyl adenosine allows researchers to investigate these functions.
* **Inflammation:** A₁ receptors are involved in inflammatory responses. Octyl adenosine can be used to study their role in different inflammatory conditions.

**2. Drug Development:** Due to its potent activity at A₁ receptors, octyl adenosine has potential for drug development in several areas:

* **Neurodegenerative Diseases:** A₁ receptor modulation is being explored as a potential therapeutic target for Alzheimer's disease, Parkinson's disease, and stroke.
* **Cardiovascular Diseases:** Octyl adenosine could have applications in treating hypertension, heart failure, and arrhythmias.
* **Pain Management:** A₁ receptor activation is linked to pain modulation, and octyl adenosine could potentially be used as a pain reliever.

**3. Cell Culture Studies:** Octyl adenosine is used in cell culture experiments to:

* **Investigate Cellular Signaling Pathways:** It allows researchers to study the effects of A₁ receptor activation on different cellular pathways and processes.
* **Develop and Screen New Drugs:** Octyl adenosine can be used as a reference compound in drug screening assays to identify new A₁ receptor modulators.

**4. Chemical Biology:** Octyl adenosine's unique chemical structure makes it a useful tool for studying:

* **Nucleic Acid Chemistry:** Understanding how modifications to adenosine affect its properties and functions.
* **Drug Delivery Systems:** Its long hydrophobic chain can be utilized to design targeted drug delivery systems.

Overall, 2-(1-octynyl)adenosine is a versatile research tool with broad applications in various fields, offering valuable insights into the functions of adenosine receptors, potential therapeutic applications, and advancements in chemical biology.

YT 146: an adenosine receptor agonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID146207
CHEMBL ID2113496
SCHEMBL ID789234
MeSH IDM0191940

Synonyms (14)

Synonym
yt 146
2-o-ado
adenosine, 2-(1-octynyl)-
yt-146
2-(1-octynyl)adenosine
2-octynyladenosine
(2r,3r,4s,5r)-2-(6-amino-2-oct-1-ynylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
90596-75-1
CHEMBL2113496 ,
bdbm50453216
SCHEMBL789234
DTXSID10238211
2-(1-octynyl)-adenosine
AKOS040754549

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
") dose-response curves for decrease in MBP due to YT-146 underwent parallel rightward shifts."( Vasodepressor mechanisms of 2-(1-octynyl)-adenosine (YT-146), a selective adenosine A2 receptor agonist, involve the opening of glibenclamide-sensitive K+ channels.
Satoh, K; Taira, N; Yamada, H; Yoneyama, F, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)2.91000.00020.552110.0000AID31417
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.27140.00011.20929.9700AID31708; AID32025; AID32027; AID32029; AID32031; AID32177
Adenosine receptor A2aHomo sapiens (human)Ki0.03590.00001.06099.7920AID1280100; AID30654
Adenosine receptor A2bHomo sapiens (human)Ki0.03990.00021.635210.0000AID30654
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki0.00670.00061.353610.0000AID33425; AID33573; AID33574
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.00670.00021.494010.0000AID33425; AID33573; AID33574
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2aHomo sapiens (human)EC50 (µMol)0.68100.00030.708110.0000AID30633
Adenosine receptor A2bHomo sapiens (human)EC50 (µMol)0.68100.00030.946110.0000AID30633
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2bRattus norvegicus (Norway rat)Ratio0.01200.00330.82929.6000AID33746
Adenosine receptor A2aRattus norvegicus (Norway rat)Ratio0.01200.00330.82309.6000AID33746
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID33573Binding affinity against adenosine A2 receptor from rat striatal membranes with 50 nM CPA using [3H]-NECA1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID227156Selectivity as A1 adenosine receptors(high affinity) using [3H]-DPCPX compared to A2 adenosine receptors using [3H]NECA in rat striatal membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID228183Dose producing 30% decrease in blood pressure of anesthetized spontaneously hypertensive rats (SHR's)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID33752Ratio of A2 to A1.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID33425Inhibition of [3H]NECA binding to adenosine A2 receptor from rat striatal membranes1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.
AID1280100Displacement of [3H]-CGS2168 from human recombinant adenosine A2A receptor2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
AID33574Binding affinity against adenosine A2 receptor from rat striatum using [3H]NECA as radioligand.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID224981Dose producing 10% decrease of heart rate in anesthetized rats (SHR)1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID30654Binding affinity against adenosine A2 receptor from human platelet membranes using [3H]NECA1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID173595Dose producing 10% decrease in heart rate of anaesthetized spontaneous hypertensive male rat(SHR)1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.
AID30794Agonistic activity at adenosine A2 receptor1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID31708Inhibition of [3H]CHA binding to adenosine A1 receptor from rat brain membranes1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.
AID33575Binding affinity against adenosine A2 receptor in rat striatal membranes using [3H]NECA as radioligand1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID228181Dose producing 10% decrease in heart rate of anesthetized spontaneously hypertensive rats (SHR's)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID235149Selectivity for adenosine receptor subtype, ratio of Ki(nM) at A1 receptor to Ki(nM) at A2 receptor1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.
AID227038Selectivity as ratio of IC50 for A1 adenosine receptor compared to EC50 for A2 adenosine receptor1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID33746Binding affinity against adenosine A2 receptor using [3H]- NECA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID177036Dose producing 30% decrease in blood pressure of anesthetized spontaneous hypertensive male rat(SHR)1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.
AID32027Binding affinity against adenosine A1 receptors from rat brain membranes using [3H]CCPA1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID32645Selectivity against adenosine A1 to A2 receptors1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID31417Inhibition of adenylate cyclase via adenosine A1 receptors in rat fat cell membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID30633Maximal NECA stimulation of adenylate cyclase via adenosine A2 receptor in human platelet membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID32026Binding affinity against adenosine A1 receptor in rat brain membranes using [3H]CHA as radioligand1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID234758Selectivity determined as Ratio of Ki(nM) of A1 adenosine receptor to the Ki(nM) of A2 adenosine receptor1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID32031Binding affinity against low affinity component of adenosine A1 receptors from rat brain membranes using [3H]-DPCPX1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID227155Selectivity as A1 adenosine receptors(high affinity) using [3H]CCPA compared to A2 adenosine receptors using [3H]-NECA in rat striatal membranes1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID32029Binding affinity against high affinity component of adenosine A1 receptors from rat brain membranes using [3H]DPCPX1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.
AID224988Dose producing 30% decrease of blood pressure in anesthetized rats (SHR)1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID32177Binding affinity against adenosine A1 receptor using [3H]-CHA or [3H]PIA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID32025Binding affinity against adenosine A1 receptor from rat brain membranes using [3H]cyclohexyladenosine as radioligand.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's17 (73.91)18.2507
2000's3 (13.04)29.6817
2010's3 (13.04)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.31 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]